GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug

Friday, GSK plc (NYSE:GSK) released the headline results of the MATINEE Phase 3 trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD), or smoker’s lungs.

The trial recruited COPD patients with broad clinical presentations of chronic bronchitis and/or emphysema who were receiving optimized inhaled maintenance therapy.

Also Read: Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population.

Participants were also required to have evidence of type 2 inflammation characterized by raised blood eosinophil count.

MATINEE met its primary endpoint with the ...